The legal challenges to President Biden’s drug price negotiation law could be on a collision course with the 2024 election.
Why it matters: Should the Medicare negotiation program survive its first courtroom showdown tomorrow, analysts say drug companies challenging the law could still have several chances to stop the program before next year’s election — which could undercut Biden’s ability to campaign on his victory over Big Pharma.
Driving the news: A federal judge in Ohio on Friday will hear oral arguments on the U.S. Chamber of Commerce’s request to halt the program before Oct. 1, the deadline for companies to agree to Medicare negotiations on the first 10 selected drugs.
Details: The judge presiding over the Chamber’s lawsuit is Michael Newman, a Trump appointee who was assigned to the case after a different judge recused himself earlier this month.
Between the lines: It’s hard to predict how these overlapping challenges might play out.
Yes, but: The Sept. 1 deadline for Medicare to announce the negotiated prices could serve as an important legal flashpoint. That could bolster drug companies’ argument that they’re being harmed before prices take effect, said Raymond James analyst Chris Meekins.
The bottom line: How the legal process plays out ahead of the 2024 election could either bolster or undermine Biden’s talking points on an issue popular with voters.